Authorization errors: a major risk for oncology

Cancer treatment is complex, delicate and often very expensive, since it involves extremely high-value items and services. Any loss of revenue directly affects the quality of care, puts the hospital’s financial health at risk and has an impact on patients. This is where one of the biggest areas of concern in oncology comes in: authorization errors.

This article explains the most common authorization errors, their impact on hospital management and how to avoid them.

What are hospital authorization errors?

Authorization is the formal permission a health plan gives for an exam, procedure or hospital admission to be carried out. It must comply with the coverage criteria and the rules of the plan and of Brazil’s National Supplementary Health Agency (ANS).

When the authorization is missing, incorrect or out of date, the hospital suffers a denial — that is, the payer refuses to pay part of the claim or even the full amount. In oncology, where a single chemotherapy cycle can cost millions, a seemingly small error tends to cause huge losses.

Authorization errors are among the main causes of denials. Making sure care is reimbursed by health plans is a matter of survival for hospitals.

Practical example

The hospital charges R$ 100,000 for oncology care, but the payer disputes it:

“The authorization for this high-cost medication was incorrect.”

Result: a R$ 20,000 denial.

But the loss does not stop there: the money does not come into the cash register, the billing department loses hours redoing and disputing the charge, and the income statement (DRE) comes under pressure. In high-cost treatments, a 5% error can turn into a six‑figure denial.

Where do authorization errors happen?

A denial for a missing or invalid authorization is one of the simplest to prevent (and, paradoxically, one of the most frequent). Errors usually arise at three critical moments:

1. Pre-authorization failure for elective treatment

This happens when the patient is admitted for scheduled treatment, such as chemotherapy, without the pre-authorization having been checked or requested correctly. Care is provided, but the problem only shows up at billing. Result: the claim is put on hold or denied.

2. Unrecorded unforeseen events

This occurs when a complication requires an additional authorization and this is not communicated to the payer.

Example: in the middle of treatment, an unexpected allergic reaction requires the use of a high-cost medication not included in the protocol. If no one requests the supplementary authorization, the item will be denied. In oncology, these costs add up to a lot.

3. Forgetting the 24‑hour rule

When a patient’s life is at risk, they are treated immediately (without prior authorization). But the hospital has about 24 hours to regularize the documentation. If the deadline is missed, the entire hospital stay can be denied.

This regularization step is often neglected once the patient is stabilized, and the hospital loses the chance to be paid for the service provided.

Why is the impact so great in oncology?

In addition to the high cost of supplies, oncology protocols change constantly, requiring new authorizations.

Doses may change with variations in weight, toxicity, hematological changes or allergic reactions, which are normal in this type of care. The treatment cycle may require new medications at any moment. And all of this needs to be authorized before care is provided.

If the authorization is not updated, the payer considers that the hospital did not follow the approved protocol. The denial is immediate. And since each episode of care uses dozens of expensive items, any discrepancy (quantity, presentation, time or the inclusion of an unplanned item) can invalidate the entire authorization.

In oncology, there are no small errors.

How to avoid denials caused by authorization errors

Although each payer has its own codes, authorization errors usually appear as:

• missing pre-authorization;

• discrepancy between what was performed and what was authorized;

• invalid or expired authorization;

• items performed without approved coverage;

• urgent care not regularized within the deadline.

These codes are easy to track in billing systems and can be monitored to prevent recurrence. The way forward involves four routines the hospital can put in place:

1. Multidisciplinary training

Errors are not born in billing; they start on the front line. So the whole team must be trained to watch the authorization cycle with great care and attention.

• Front desk: training in eligibility and forms.

• Nursing: recording every complication.

• Pharmacy: checking before dispensing.

• Medical team: clear description of protocol changes.

2. Technology as a prevention tool

Systems that flag the need for reauthorization, dose discrepancies and the use of high-cost materials reduce failures even before care is provided.

3. Double check before expensive medications

A simple checklist, validated before administration, eliminates most discrepancies.

4. Daily audit of active authorizations

It is essential to review validity, quantity, extra items, pending reauthorizations and complications.

The payer’s role in the authorization process

Each health plan has its own criteria, forms and deadlines for granting authorization. What one accepts, another may refuse, and these differences directly affect oncology billing.

ANS Normative Resolution 465, which sets the maximum deadlines for authorizing elective and urgent procedures, is the regulatory floor that all payers must respect. For elective procedures, the deadline is up to 21 business days. For urgent and emergency care, treatment must be guaranteed immediately. Knowing these deadlines protects the hospital from authorizations denied on criteria that go beyond what the rule allows.

Reauthorization: a point of attention in oncology

The initial pre-authorization is only the beginning. In long cancer treatments, the authorization must be renewed periodically, and it is in this reauthorization process that many hospitals silently lose revenue.

Each payer sets its own validity cycles. An authorization for chemotherapy may expire after 30, 60 or 90 days, depending on the contract. If no one actively tracks these deadlines, the hospital keeps treating the patient under an expired authorization and only discovers the problem at billing.

The risk is even greater when the protocol changes during treatment. A new phase, the addition of a supportive medication or a change of therapeutic regimen requires a new authorization, not just a renewal. Hospitals without systematic control of these changes accumulate denials that could have been avoided with a simple alert at the right time.

How to identify authorization denial patterns at the hospital

Authorization denials are rarely isolated events. When an error appears once, it tends to repeat in the same department, with the same payer or in the same type of procedure. Identifying these patterns turns denial management from reactive to preventive.

The starting point is to classify the denials received by type, payer, department and period. With this mapping, it is possible to identify, for example, that 60% of authorization denials come from a single health plan, or that the outpatient chemotherapy department accounts for most of the cases of missing pre‑authorization.

Based on this data, the hospital can renegotiate criteria with the payer, step up training in the critical department or adjust the authorization request flow for that specific type of care.

Clinical documentation as the basis for authorization

An approved authorization does not guarantee payment if the clinical documentation does not support what was billed. In oncology, the quality of the clinical record is an even more important part of the billing process.

An incomplete medical record, generic nursing notes or a medical report without a precise description of the therapeutic regimen are frequent reasons for denials even when care had a valid authorization. The payer disputes not the authorization itself, but the consistency between what was authorized and what the documentation proves.

The way forward is to treat the clinical record as a revenue cycle requirement, not just a care obligation. Clear descriptions of protocol changes, justifications for the use of non-standard medications and detailed records of complications build a documentary foundation that supports the charge and reduces the risk of denial in the payer’s audit.

In oncology, there is no margin for error

Preventing authorization errors in oncology is a matter of financial survival. The high cost of supplies, the frequency of protocol changes and the complexity of care make every stage of the process critical to the hospital’s financial health.

By investing in processes, training and technology, institutions ensure that the high-complexity care provided to patients is properly and fully paid for. In this context, tools based on artificial intelligence help bring consistency to daily work.

Rivio’s platform supports hospitals in preventing denials, keeping authorizations in order and standardizing the most sensitive flows of the revenue cycle, with greater financial predictability and less rework for teams.

Less bureaucracy, more agility and the possibility of more patient‑centered care.

FAQ: frequently asked questions about authorization errors in oncology

Why does oncology concentrate so many authorization errors?

Oncology protocols change frequently: doses vary with weight, toxicity and response to treatment, and new medications can be added at any moment. Each change requires a new authorization. With so many simultaneous variables, any failure in recording leads to an immediate denial.

What is the deadline for regularizing an authorization in an oncology emergency?

In urgent care, the hospital has about 24 hours to notify the payer and request a retroactive authorization. In oncology, where complications such as allergic reactions and toxicity are common, this deadline is often missed after the patient is stabilized, resulting in a denial of the entire hospital stay.

Which oncology items carry the highest risk of authorization denials?

High-cost chemotherapy drugs, medications outside the standard protocol and special materials are the items with the highest incidence of denials. Any discrepancy in dose, presentation or the inclusion of an unplanned item can invalidate the entire authorization, and in oncology these items make up most of the claim.

How can you avoid denials when the oncology protocol changes during treatment?

The way forward is to record the change immediately and request reauthorization before the new medication or dose is administered. A checklist validated by the medical team and the pharmacy, integrated into the billing system, significantly reduces discrepancies between what was authorized and what was performed.